Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
Randy Taplitz(CancerCare Manitoba), Christopher R. Flowers(CancerCare Manitoba), Amelia Langston(CancerCare Manitoba), Eric J. Bow(CancerCare Manitoba), Jennie R. Crews(CancerCare Manitoba), Lynne Strasfeld(CancerCare Manitoba), Michelle Rajotte(CancerCare Manitoba), Erin B. Kennedy(CancerCare Manitoba), Charise Gleason(CancerCare Manitoba), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Kenneth V. I. Rolston(CancerCare Manitoba), Douglas K. Hawley(CancerCare Manitoba)
Cited by 574
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782